Trigemina Announces Expansion of Phase II Study of TI-001 for Chronic Migraine
MORAGA, CA, Feb. 6, 2014 – Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced it has...
View ArticleTrigemina expands Phase II trial of TI-001 for chronic migraine
Pharmaceutical Business Review – US-based biopharmaceutical firm Trigemina has expanded its Phase II clinical trial for TI-001, intranasal oxytocin, beyond Chile to include sites in Brisbane and...
View ArticlePain in the brain? Trigemina seeking to break the barrier
Bioworld Today – No matter what the cause – cluster headaches, migraines, cancer, nerve damage, temporomandibular joint disorder, trigeminal neuralgia or another disorder – chronic head pain remains...
View ArticleTrigemina Presented at American Headache Society 56th Annual Scientific Meeting
Chief Scientist Dr. David Yeomans Discussed Nasal Oxytocin Spray for Treatment of Chronic and Episodic Migraine MORAGA, CA., July 1, 2014 – Trigemina, Inc., a biopharmaceutical company focused on the...
View ArticleTrigemina Selected to Present at Cavendish Global Health Impact Forum
Forum uniquely brings together leading family offices and their foundations seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences La Jolla, Calif. May...
View ArticleTrigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer
Moraga, Calif. August 4, 2015—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced today that the...
View ArticleTrigemina to Present at the BIO 14th Annual BIO Investor Forum
Moraga, Calif. October 15, 2015—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that Charles Yeomans, the...
View ArticleTrigemina Publishes Data Demonstrating that the Activation of Oxytocin...
Moraga, Calif. December 3, 2015—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today the publication of...
View ArticleTrigemina to Present at Biotech Showcase 2016
Moraga, Calif. January 6, 2016—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will...
View ArticleTrigemina to Present at the BIO Asia 2016 International Conference
Moraga, Calif. March 9, 2016—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will present...
View ArticleTrigemina to Present at the BIO-Europe Spring 2016 Conference
Moraga, Calif. March 29, 2016—Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of targeted neurological drug therapies, announced today that the company will...
View ArticleVIDEO: New drug trial offers hope for migraine sufferers
Could not use HTML 5 or Flash for playback. You can download the file as MPEG4/H.264 or Ogg Theora file. Original post:...
View ArticleTrigemina looks to raise USD 22m in Series B this year; to retain advisor – CEO
Trigemina, the Moraga, California-based developer of nasally delivered analgesic drug formulations, is looking to raise USD 22m in its Series B round this year, President and CEO Charles Yeomans said....
View Article